FEI PARTNERS WITH FIVE PHARMACEUTICAL COMPANIES, THE MEDICAL RESEARCH COUNCIL AND THE UNIVERSITY OF CAMBRIDGE TO FORM CRYO-EM RESEARCH CONSORTIUM
HILLSBORO, Ore. and LONDON, April 04, 2016 -- FEI (NASDAQ:FEIC) has partnered with five pharmaceutical companies:
Astex Pharmaceuticals, AstraZeneca, GlaxoSmithKline, Heptares Therapeutics, and UCB; the Medical Research Council Laboratory of Molecular Biology (MRC-LMB);
and the University of Cambridge’s Nanoscience Centre, to form the “Cambridge Pharmaceutical Cryo-EM Consortium,” which is the first of its kind worldwide.
As part of the three-year agreement,
FEI will provide sample preparation and data collection services on a Titan Krios™ cryo-transmission electron microscope (cryo-EM) to the consortium companies for early-stage drug discovery research.
The five companies involved in the consortium will share access to the microscope with colleagues from the MRC-LMB and the University of Cambridge in return for expert guidance on the use of cryo-EM technology.
FEI’s Titan Krios will be installed at the Nanoscience Centre in May.
Richard Henderson, pioneer in the field of cryo-EM at MRC-LMB, states,
"It is delightful to know that the development of cryo-EM, which many people have worked on for many years, has now reached mainstream structural biology.
It is particularly satisfying that pharmaceutical companies are keen to evaluate the approach for drug development."
FEI PARTNERS WITH FIVE PHARMACEUTICAL COMPANIES, THE MEDICAL RESEARCH COUNCIL AND THE UNIVERSITY OF CAMBRIDGE TO FORM CRYO-EM RESEARCH CONSORTIUM
HILLSBORO, Ore. and LONDON, April 04, 2016 -- FEI (NASDAQ:FEIC) has partnered with five pharmaceutical companies:
Astex Pharmaceuticals, AstraZeneca, GlaxoSmithKline, Heptares Therapeutics, and UCB; the Medical Research Council Laboratory of Molecular Biology (MRC-LMB);
and the University of Cambridge’s Nanoscience Centre, to form the “Cambridge Pharmaceutical Cryo-EM Consortium,” which is the first of its kind worldwide.
As part of the three-year agreement,
FEI will provide sample preparation and data collection services on a Titan Krios™ cryo-transmission electron microscope (cryo-EM) to the consortium companies for early-stage drug discovery research.
The five companies involved in the consortium will share access to the microscope with colleagues from the MRC-LMB and the University of Cambridge in return for expert guidance on the use of cryo-EM technology.
FEI’s Titan Krios will be installed at the Nanoscience Centre in May.
Richard Henderson, pioneer in the field of cryo-EM at MRC-LMB, states,
"It is delightful to know that the development of cryo-EM, which many people have worked on for many years, has now reached mainstream structural biology.
It is particularly satisfying that pharmaceutical companies are keen to evaluate the approach for drug development."
・・・